

Original Paper

MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells

Jiahui Chu^a Yongfei Li^a Xuemei Fan^b Jingjing Ma^b Jun Li^a Guangping Lu^a
Yanhong Zhang^a Yi Huang^d Wei Li^a Xiang Huang^a Ziyi Fu^{a,b} Yongmei Yin^{a,e}
Hongyan Yuan^{b,c}

^aDepartment of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, ^bNanjing Maternal and Child Health Medical Institute, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, China, ^cDepartment of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, ^dDepartment of Pharmacology and Chemical Biology, Magee Women's Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, USA, ^eJiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China

Key Words

Triple-Negative Breast Cancer • MiR-4319 • E2F2 • Cancer stem cell (CSC)

Abstract

Background/Aims: High levels of cancer stem cells (CSCs) in patients with triple-negative breast cancer (TNBC) correlate with risk of poor clinical outcome and possibly contribute to chemoresistance and metastasis in patients with highly malignant TNBC. Aberrant microRNA expression is associated with the dysfunction of self-renewal and proliferation in cancer stem cells, while there is little information about the TNBC-specific microRNAs in regulating CSC ability. **Methods:** Solexa deep sequencing was performed to detect the expression levels of TNBC or non-TNBC stem cells (CSCs) microRNAs. Mammosphere formation assay, qRT-PCR and the xenograft model in nude mice were performed. Bioinformatic analysis and microarray were used to select the target gene, and luciferase reporter assays were used to confirm the binding sites. **Results:** Solexa sequencing data exhibited differential expression of 193 microRNAs between TNBC and non-TNBC stem cells. The gene ontology analysis and pathways analyses showed that genes were involved in the maintenance of stemness. MiR-4319 could suppress the self-renewal and formation of tumorspheres in TNBC CSCs through E2F2, and also inhibited tumor initiation and metastasis *in vivo*. Moreover, increased E2F2 could reverse

J. Chu, Y. Li and X. Fan contributed equally to this work.

Yongmei Yin
and Hongyan Yuan

Department of Oncology, First Affiliated Hospital, Nanjing Medical University
No.300 Guangzhou Rd, Nanjing 210029 (China) Tel. +86 25 83710040
Fax +86 25 83710040, E-Mail yymyin@njmu.edu.cn/ym.yin@hotmail.com/dryhy@hotmail.com

the effect of miR-4319 on the self-renewal in TNBC CSCs. **Conclusions:** MiR-4319 suppresses the malignancy of TNBC by regulating self-renewal and tumorigenesis of stem cells and might be a remarkable prognostic factor or therapeutic target for patients with TNBC.

© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Triple-negative breast cancer (TNBC) constitutes 10% to 20% of all breast cancers [1, 2] and is characterized by tumors with a lack of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and higher rates of metastasis and poorer prognosis [3]. The incidence rate of TNBC has increased continuously over the past decades [4], especially in young women. A persistent problem among the young cohort is that some women ignore their regular physical examination, which makes early mammographic screening more difficult [5, 6]. Women in whom TNBC is diagnosed rarely benefit from endocrine therapy or chemotherapy, and as a result, TNBC has poor prognosis and more than 70% mortality in metastatic TNBC [1]. Furthermore, TNBC appeared with higher tumor heterogeneity than non-TNBC. Recently, TNBC has been divided into six subtypes based on the Lehmann/Pietenpol classification [7], and current chemotherapy treatments already evoke diverse responses and clinical outcomes in patients with TNBC. Consequently, there is still no optimized standard form of chemotherapy for TNBC, leading to an urgent need for the development of effective treatments for this malignancy. Several studies have suggested that cancer stem cells (CSCs) correlated positively with the malignant degree of breast cancer, and might be responsible for metastasis and drug resistance of patients with TNBC [8, 9].

CSCs, a subpopulation of cancer cells, are capable of initiating tumorigenesis by undergoing self-renewal and differentiation [10]. Breast cancer stem cells (BCSCs) have been defined and prospectively isolated by the cell surface markers CD44+, CD24-, and ALDH+ [11]. BCSCs play important roles in breast cancer, such as promoting tumor initiation, stimulating metastasis, and inducing chemoresistance [12]. In addition, promising evidence shows the existence of a positive association between the proportion of stem cells in tumors and disease progression, and that high levels of CSCs correlate with risk of metastasis and poor clinical outcome [13]. TNBC has been identified to comprise more CD44+/CD24-cells (CSCs) than non-TNBC in solid tumors [14, 15], which might contribute to chemoresistance and metastasis in patients with highly malignant TNBC.

It has been confirmed that microRNAs play a role in regulating biological processes through downstream target genes. Specifically, anti-microRNAs agents might be a new strategy for the development of clinical antitumor therapy [16, 17]. Over the past few decades, it has been demonstrated that appropriate combinations of microRNAs were closely related to the malignant progression of breast cancer [18]. Several microRNA clusters, involving miR-374-5p, miR-126-3p, and miR-27b-3p, are linked to development, recurrence, and response to therapeutic treatments in breast cancer [19, 20]. Previous studies have also suggested that aberrant microRNA expression contributes to the dysfunction of self-renewal and proliferation in cancer stem cells [21, 22], such as let-7 and miR-30, which could reduce the ability of self-renewal and mammosphere formation in BCSCs [22, 23]. Over the past few decades, protein markers such as ER, PR, and HER2, which are well known to stimulate the development of non-TNBC, have been used to differentiate TNBC and non-TNBC, and therapeutic agents, which targeted ER or HER2, inhibited non-TNBC efficiently. There is little progression in the development of treatment for TNBC. It has been proposed that CSCs might contribute to the malignancy of TNBC, and the correlation between CSC proportion and microRNAs might be helpful to find the potential therapeutic targets for TNBC by controlling CSC function.

Currently, there is little information about the TNBC-specific microRNAs in regulating CSC ability. We detected the TNBC-derived, CSCs-related microRNAs expression panel, and found an unknown miR-4319 especially dysregulated in TNBC CSCs. In this study, we aimed to identify the effect of miR-4319 on BCSCs and determine the underlying mechanism.

Materials and Methods

Cell culture

The human breast cancers BT474, MCF-7, SKBR3, MDA-MB-468, MDA-MB-231 and MDA-MB-453 were all obtained from American Type Culture Collection (ATCC, Manassas, VA). BT474 and SKBR3 were cultured in RPMI-1640 medium (Gibco); MDA-MB-453 was cultured in L15 medium (Gibco); MCF-7, MDA-MB-231 and MDA-MB-468 were cultured in DMEM medium (Gibco); supplemented with 10% (v/v) fetal bovine serum (Gibco), 100 U/ml penicillin (Gibco), and 100 U/ml streptomycin (Gibco) at 37°C in a humidified atmosphere containing 5% CO₂ [24].

Flow Cytometric analysis

Anti-Human/Mouse CD44 FITC (eBioscience) and Anti-Human CD24 PE (eBioscience) were used for flow cytometric analysis [25]. Cells were harvested by trypsinization and washed once in PBS. Next, cells were counted and resuspended in cold PBS at a concentration of 1.0×10^7 cells per 100ul. Staining was performed by incubating 100ul cells with 20ul antibody in 4°C for 25 min.

Mammosphere culture

The cancer stem cells were plated into ultra-low attachment six well plates (Corning 3471) at a density of 2000 cells per well [26]. The cancer stem cells were cultured with MammoCult™ Human Medium Kit (Stem cell technologies, Vancouver, BC, Canada) according to manufacturer's guidelines [27]. Mammospheres were resuspended in trypsin/EDTA and passaged by centrifuging at 300g for 10 min in 7-14 days. Secondary spheres were used to analyze the efficiency of mammosphere-formation by assessing the number of spheres formed per cells seeded [28]. Then formed spheres were counted manually and representative images were acquired [26] using Leica DMI3000B microscope with Leica Microsystems Framework.

RNA extraction, construction and solexa sequencing of small RNA libraries

Total RNA was isolated from non-TNBC stem cells (BT474, MCF-7, SKBR3) and TNBC stem cells (MDA-MB-468, MDA-MB-231, MDA-MB-453) using Trizol (Ambion, Carlsbad, CA), and then assessed by Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA). Two small RNA libraries of BT474 CSC, and MDA-MB-468 CSC were established by following the described methods [29]. We filtered the low quality reads according to base quality value. Small RNAs (18–30 nt), acquired from the total RNA, with 5' and 3' adaptors ligated to them, were subsequently transcribed into cDNA using RT Master Mix (Takara, Dalian, China) followed by PCR amplification. The PCR products were purified and submitted to Solexa sequencing (Illumina, CA) Beijing Genomics Institute (BGI, Shenzhen, China). Reads (counts < 2) were discarded when calculating the microRNA expression. Fold-change (≥ 2.0 or ≤ 0.5) of the reads of sequenced microRNAs was employed to study the differential expression profiles of the CSC microRNAs in BT474 and MDA-MB-468 groups based on TagCount_ALL_Isoform data.

Sequencing data analysis

The initial sequence reads were generated by Illumina Genome Analyzer. To identify conserved microRNAs, the filtered sequences were originally applied to miRBase 21.0 (<http://www.mirbase.org/>) with BLASTN. The criterion was implemented based on a reported microRNA protocol [30]. All unannotated RNAs were subjected to novel microRNA prediction using Mireap software (<https://sourceforge.net/projects/mireap/>). The expression of known microRNAs was compared between the two groups to screen differentially expressed microRNAs.

Gene ontology and KEGG pathways mapping analysis

The possible targets of differentially expressed microRNAs were predicted via Mirbase, Target-Scan, and miRanda programs with the default parameters. MicroRNA target intersections of the three programs were regarded as potential microRNA target genes. The MAS3 program (<http://bioinfo.capitalbio.com/mas3/>) was used to annotate the functions of potential microRNA target genes via the Gene Ontology (GO) (<http://www.geneontology.org/>) project and the relative pathways were analyzed via the Kyoto Encyclopedia of Genes and Genomes (KEGG) program (<http://www.genome.jp/kegg/pathway.html>).

Real-time PCR quantification of microRNA

A stem-loop primer based PCR assay was used to validate the differentially expressed microRNAs. Total RNA was extracted from TNBC CSCs (MDA-MB-468, MDA-MB-231, MDA-MB-453) and non-TNBC (BT474, MCF7, SKBR3) using Trizol (Life Technologies, Shanghai, China), then was subjected to reverse transcription and qRT-PCR using the Bulge-Loop™ microRNA qRT-PCR Starter Kit (Ribobio, Guangzhou, China). qRT-PCR was performed on ABI 7900 PCR System (Applied Biosystems, USA). After denaturation, the reactions were conducted as the following: 2s at 95°C, 20s at 60°C and 10s at 70°C for 40 cycles. Results were expressed as ΔC_t values and the expression of snRNA U6 was served as normalization control [31]. The RNA expression of the specific stem cell properties (CD24, CD44, Oct4, ALDH, and Nanog [32]) was analyzed by qRT-PCR (SYBR Green Master, Takara, Dalian, China). qRT-PCR was performed with a Roche LightCycler 96 Real-Time PCR System. Data was analyzed by the $2^{-\Delta\Delta C_t}$ method with normalization to GAPDH. Partial primer sequences are listed at Table 1.

Table 1. Partial primers for qRT-PCR of microRNAs

Seqname	Location	Mature sequence	Primer (5'-3'; Forward: F, Reverse: R)
hsa-miR-205	1q32.2	UCCUUCAUUCCACCGGAGUCUG	F:AGCCGTCCTTCATTCCACC R: CAGTGGGTGTCGTGGAGT
hsa-miR-222	Xp11.3	AGCUACAUUGGCUACUGGGU	F:CGCTCAAGTACATCTGGC R: CAGTGGGTGTCGTGGAGT
hsa-miR-135b	1q32.1	UAUGGCUUUUAUUCUUAUGUGA	F:CGTCGTATGGCTTTTCATTCCT R: CAGTGGGTGTCGTGGAGT
hsa-miR-4319	18q12.3	UCCUGAGCAAAGCCAC	F:GCACAGCTCCCTGAGCAA R: CAGTGGGTGTCGTGGAGT
hsa-miR-181a-2-3p	9q33.3	ACCACUGACCGUUGACUGUACC	F:GATCGACCACTGACCGTTGAC R: CAGTGGGTGTCGTGGAGT
hsa-miR-30a-5p	6q13	UGUAAACAUCUUGCAGUGGAAG	F:AGCCCGTGTAAACATCTCCGA R: CAGTGGGTGTCGTGGAGT

Lentiviral-mediated miRNA overexpression and knockdown

The CD44+CD24- human BCSCs were isolated by flow cytometry and then were infected by 20 moi of miR-4319-expressing lentivirus, miR-4319-inhibiting lentivirus or control lentivirus by spin infection for 2 hours followed by incubation at 37° C to generate stable expression cell lines (MDA231-miR-4319-OE, MDA231-miR-4319-KD and MDA231-NC). The expression of miR-4319 in MDA231-miR-4319-OE, MDA231-miR-4319-KD and MDA231-NC was confirmed via real-time PCR.

In vivo

Infected CD24-CD44+ cells (MDA231-miR-4319-OE, MDA231-miR-4319-KD and MDA231-NC) were injected into mammary fat pad of female immunodeficient mice mixed with Matrigel (BD Biosciences) at the concentration of 5×10^4 /150ul. After 45 days, all the mice were sacrificed to harvest the xenograft. All experiments were carried out under the approval of the Administrative Panel on Laboratory Animal Care of Stanford University. The liver and lung tissues were fixed in 4% paraformaldehyde in continuing dehydration in ascending grades of Ethanol (Merck, Germany), cleared and embedded in xylol and paraffin, respectively. Sections of 5 μ m were taken, stained with Hematoxylin-Eosin (H-E), and investigated under the light microscope (Leica DMI3000B microscope).

Luciferase reporter assays

MDA231 cells were co-transfected with lentivirus (miR-4319-expressing, negative control) and 0.5 μ g of dual luciferase reporter plasmid containing wild-type or mutated E2F2 3'UTRs (Synbio technologies, Suzhou) using Lipofectamine 2000 (Life Technologies Corporation). 48h post-transfection luciferase activity was quantified following the instruction of Dual Luciferase Reporter kit (Promega Inc).

Statistical analysis

MicroRNAs expressions in the treated and the control cells were identified by applying one way ANOVA (analysis of variance) method followed by post-hoc Tukey's analysis. A p-value of less than 0.05 was considered statistically significant (p value<0.05) and each experiment was conducted in triplicate. Computer-based calculations were performed using SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA).

Results

Isolation and identification of CSCs

BCSC-enriched subpopulations were sorted from MDA-MB-468 (ER-, PR-, HER2-), MDA-MB-231 (ER-, PR-, HER2-), MDA-MB-453 (ER-, PR-, HER2-), BT474 (ER+), MCF-7 (ER+), and

SKBR3 (HER2+) with CD24 and CD44 cell-surface markers by flow cytometric analysis (Fig. 1A, data showed partially). The proportion of CD44+CD24- cells in TNBC was higher than non-TNBC, which is consistent with previous reported results [33]. The ability of tumorsphere formation was also examined and the data showed that the isolated single cell (both TNBC- and non-TNBC-CSCs) could form dominant tumorspheres in 7 to 14 days (Fig. 1B). However, TNBC-derived CSCs (MDA-MB-468, MDA-MB-231, MDA-MB-453) appeared to have a stronger ability to form tumorsphere in less than 7 days. The number of tumorspheres was counted after 7 days. The results showed that the tumorsphere formation ability of MDA-MB-468 ($54.4\% \pm 10.96\%$) was stronger than that of BT474, and the tumorsphere formation ratio of MDA-MB-468 ($54.4\% \pm 10.96\%$) was higher than BT474 ($36.3\% \pm 7.02\%$) ($p > 0.05$). The same situation was also observed in MDA-MB-231, MDA-MB-453, MCF-7, and SKBR3. The expression of the specific surface markers (CD44, ALDH, Oct4, and Nanog) was significantly increased, whereas the expression of CD24 was significantly decreased in cancer stem cells (Fig. 1B, partial data shown).

Solexa sequencing data showed different expression of 193 microRNAs between the two small RNA libraries

Total RNA of each sample was used to prepare the microRNA sequencing library. The Solexa [34] data showed that microRNAs were the major components of small RNAs (<30 bp) in the BCSCs. The 193 microRNAs were expressed differentially between the two small RNA libraries ($P < 0.05$), in which 112 microRNAs were upregulated and 81 were downregulated in MDA-MB-468 CSC comparing to BT474 CSC (Fig. 2A, 2B).

Identification of known microRNAs

Stem-loop real-time PCR quantification was implemented to verify 10 microRNAs that were selected from the Solexa sequencing microRNA expression results in TNBC (MDA-MB-468, MDA-MB-231, MDA-MB-453) and non-TNBC (BT474, MCF7, SKBR3) CSCs. Four of 10 (hsa-miR-205, hsa-miR-181-2-3p, hsa-miR-222-3p, and hsa-miR-135) were upregulated and 2 microRNAs (hsa-miR-30a and hsa-miR-4319) were stably downregulated in TNBC CSCs (MDA-MB-468, MDA-MB-231, MDA-MB-453) (shown in Fig. 3).




Fig. 1. Isolation and identification of CSCs. BCSC-enriched subpopulations were sorted from MDA-MB-468 (ER-, PR-, HER2-) and BT474 (ER+) with CD24 and CD44 cell surface markers by flow cytometric analysis (1A). The expression of the specific surface markers was significantly changed in CSCs (1B).




Fig. 2. Different expression of 193 microRNAs between the MDA-MB-468 and BT474 CSCs. Solexa sequencing data showed the differences in microRNA expression between TNBC and non-TNBC through cluster mapping (A) and scatterplot (B).

112 microRNAs were upregulated and 81 were downregulated in MDA-MB-468 CSC comparing to BT474 CSC (Fig. 2A, 2B).

Gene ontology and pathway analysis of TNBC-CSCs related microRNAs

To further understand the biological functions of the microRNAs, target genes were applied to MiRbase, MiRanda, and TargetScan (<http://www.targetscan.org>); there were 236 target genes down-regulated and 523 target genes upregulated with a value of $P < 0.05$. The microRNA-target genes were associated with the following biological processes: stem cell development, embryonic morphogenesis, single-organism development, multicellular organismal development, cell differentiation, system development, organ development, regulation of metabolic process, regulation of stem cell differentiation, and response to chemicals (Fig. 4A). The microRNA-target genes were also involved in cellular components (Fig. 4B) and potentially regulated almost 201 gene ontology (GO) terms of molecular function of which the top three were mRNA binding, protein binding, and enzyme binding (Fig. 4C). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that a total of 55 pathways were identified in which most were associated with the function of CSCs, such as signaling pathways regulating pluripotency of stem cells, Notch signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, estrogen signaling pathway, Janus kinase/signal transducers and activators of transcription signaling pathway, forkhead transcription factors of the O class signaling pathway, mechanistic target of rapamycin signaling pathway, and transforming growth factor beta signaling pathway (Fig. 4D). The brief mechanism diagram was listed in Fig. 4F, and the orange- labeled proteins were predicted to be dysregulated between TNBC-CSC and non-TNBC-CSC, which indicated

Fig. 3. Identification of known microRNAs. We validated the expression level of the dysregulated microRNAs in TNBC and non-TNBC CSCs. Six microRNAs (hsa-miR-205, hsa-miR-181-2-3p, hsa-miR-222, hsa-miR-135, hsa-miR-30a-5p, and hsa-miR-4319) were stably upregulated in TNBC CSCs (MDA-MB-468, MDA-MB-231, MDA-MB-453). (Each experiment was repeated in triplicate independently, * $p < 0.05$).





Fig. 4. To explore the potential functions of the dysregulated microRNAs in TNBC-derived CSCs, we performed GO and KEGG pathway analysis. The microRNA-target genes were associated with the following biological processes: stem cell development, embryonic morphogenesis, cell differentiation, and regulation of stem cell differentiation (4A). These gene products were mainly located in cellular component (4B); the molecular functions of these genes mainly included mRNA binding, protein binding, and enzyme binding (4C). The KEGG pathway analysis results indicated that these genes were involved in regulating the function of cancer stem cells, such as the signaling pathway regulating pluripotency of stem cells, the Notch signaling pathway, and the estrogen signaling pathway (4D). The brief mechanism diagram is listed in 4F.



that these proteins probably participated in maintaining the high pluripotency of TNBC-CSC. Most importantly, our analysis suggested that the microRNAs played important roles in tumor initiation and development.

Mir-4319 regulated the self-renewal capacity of BCSCs

We performed function analysis of miR-4319 in MDA-MB-231 CSCs. The expression of miR-4319 in stable cell lines (MDA231-miR-4319-OE, MDA231-miR-4319-KD, and MDA231-NC) was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) (Fig. 5B). Compared to the miR-4319-NC group, a decrease in tumorsphere-forming efficiency was observed in the miR-4319-OE group and an increase was observed in the miR-4319-KD group. Tumorspheres in the miR-4319-KD group grew faster than that in the miR-4319-NC group and the results in the miR-4319-OE group showed the reverse. The number of tumorspheres in suspension was expanded in the miR-4319-KD group compared to the control group (Fig. 5A, 5C). qRT-PCR demonstrated that inhibition of miR-4319 markedly increased the transcript abundance of Sox2, Oct4, Nanog, and CD133, which were specific for isolated CSCs (Fig. 5D).

In vivo

The xenograft model of TNBC CSCs was adopted to assess the role of miR-4319 in tumor initiation as xenotransplantation remains the gold standard for the balance between BCSC self-renewal and differentiation *in vivo*. A higher number of macroscopic hepatic metastases could be observed in the MDA231-miR-4319-KD group, and few macroscopic hepatic metastases could be seen in the MDA231-miR-4319-OE group (Fig. 6A). Compared to control, the overexpression of miR-4319 inhibited tumor formation, and knockdown of miR-4319 promoted tumor initiation and extensive metastases, which indicated that miR-4319 was a regulator of CSC functions. MiR-4319 knockdown resulted in a higher number of growing tumors than in the control group, which showed the strong ability of miR-4319 on regulation of the tumorigenicity expected from TNBC CSCs (Fig. 6B). Hematoxylin and eosin staining showed metastatic focus in liver (Fig. 6C) and lung (Fig. 6D); the same results were seen via visual inspection. These results indicate that miR-4319 knockdown could significantly enhance the tumorigenesis of stem cells and consequently be responsible for extensive metastasis in TNBC.

Identification of E2F2 as a direct target of miR-4319

Gene expression profiles of MDA231-miR-4319-OE group and MDA231-NC group were determined using Illumina HiSeq 4000. Among the various genes expressed, E2F2 has been known to maintain the pluripotency of human embryonic stem cells and three miR-4319 binding sites (M1, M2, M3) on E2F2 3' untranslated region (UTR) were predicted by TargetScan (Fig. 7A). Both qRT-PCR and western blot results showed that overexpression of miR-4319 in MDA231-CSCs significantly decreased the expression of E2F2 (Fig. 7B, 7C). The 3'UTR of E2F2 was cloned into pGL3-control vector and the specific binding sites were confirmed by luciferase assays via mutation of the three sites. Overexpression of miR-4319 greatly




Fig. 5. To investigate the regulation of miR-4319 on self-renewal capacity BCSCs, we performed function analysis. Overexpression of miR-4319 inhibited tumorsphere formation in both size and number (5A, 5B). The scale bar is 50 μ m. The expression of the specific surface markers was significantly downregulated in CSCs when miR-4319 was overexpressed, and vice versa (5C).

reduced luciferase activity of the reporter gene by almost 50% and when the mismatch mutation was introduced into the region of M1, M2, and M3 at the same time, the inhibition of luciferase activity was almost abolished (Fig. 7C). The results demonstrated that miR-4319 could bind to the three sites (M1, M2, and M3) on the E2F2 3'UTR to regulate its biological function in CSCs.

Mir-4319 regulated the self-renewal capacity of BCSCs through E2F2

A rescue experiment has been performed to confirm the function of E2F2 in the MDA231-miR-4319-OE/KD group. MDA231-miR-4319-OE was transfected with E2F2 vector or empty vector (E2F2+ or control-1); MDA231-miR-4319-KD was transfected with E2F2-small interfering RNA or scrambled control (E2F2 siRNA or control-2). The expression levels of E2F2 were determined by qRT-PCR and western blot analysis (Fig. 8A). E2F2 overexpression accelerated the formation of tumorspheres and increased the expression of the specific stem cell surface markers (Sox2, Oct4, Nanog and CD133), and both functions were suppressed by miR-4319-OE in TNBC CSCs; in contrast, E2F2 depletion reduced the CSC functions in miR-4319-KD CSCs (Fig. 8B). MiR-4319 inhibited the formation of tumorspheres in TNBC CSCs, which was partially overcome by overexpressing E2F2.

These results showed that miR-4319 could inhibit the stem cell characteristics of TNBC CSCs through regulating E2F2 expression levels.

Discussion

TNBC is a highly aggressive cancer accompanied by poor prognosis, with no effective treatments currently available. Additionally, women with TNBC are more




Fig. 6. The xenograft model was used to assess the role of mir-4319 in tumor-initiating. Macroscopic hepatic metastases were more prevalent in the miR-4319-KD group (35 ± 10.35) than the NC group (6.75 ± 7.88). Only a few hepatic metastases (2.0 ± 4.1) could be seen in the miR-4319-OE group (6A and 6B showed representative pictures and number of metastatic focus, respectively). Hematoxylin and eosin staining showed metastatic focus in liver (6C) and lung (6D), which indicated the same results with visual inspection.

Fig. 7. Identification of E2F2 as a direct target of miR-4319. qRT-PCR and western blot analysis both showed overexpression of miR-4319 in MDA231-CSCs decreased the expression of E2F2 mRNA (7B, 7C). Three predicted binding sites (M1, M2, M3) in the E2F2 3' UTR of miR-4319 were identified by TargetScan. The numbers represented the targeted position in the 3' UTR of E2F2 and red letters denote mutations that disrupt base pairing of M1~3 (7A). The three predicted sites were cloned into pGL3-Control vector and cotransfected with miR-4319, respectively containing wild-type, M1~3, M1+2, M1+3, M2+3, and M1+2+3. Dual luciferase assay showed that miR-4319 regulated E2F2 expression by targeting M1~3 (7D). The activity of firefly luciferase was normalized to that of renilla luciferase in each experiment. The luciferase activity in cells transfected with control miRNA (NC) was defined as 100%. The values represent the mean \pm standard deviation from at least three independent experiments. The two-tailed t-test was used to statistically analyze the results ($p < 0.05$).





Fig. 8. MiR-4319 regulated the self-renewal capacity of BCSCs through E2F2. MDA231-miR-4319-OE was transfected with E2F2 vector or empty vector (E2F2+ or control-1); MDA231-miR-4319-KD was transfected with E2F2-small interfering RNA or scrambled control (E2F2 siRNA or control-2). The expression levels of E2F2 were determined by qRT-PCR (8A, top) and western blot analysis (8A, bottom). GAPDH was used as control. The overexpression of E2F2 promoted the formation of tumorspheres in miR-4319-OE CSCs and also increased specific surface markers, and vice versa (8B). The scale bar is 50 μ m. The values represent the mean \pm standard deviation from at least three independent experiments. The two-tailed t-test was employed used to statistically analyze the results ($p < 0.05$).



likely to experience chemotherapy drug resistance. Previous studies have suggested that CSCs were positively related to the malignant degree of breast cancer and might be responsible for metastasis and drug resistance in TNBC [8, 9]. In this study, we isolated CD44+CD24- cells to enrich CSCs from TNBC (MDA-MB-468, MDA-MB-231, MDA-MB-453) and non-TNBC (BT474, MCF-7, SKBR3) by flow cytometric analysis. The results of microsphere formation showed that TNBC-derived CSCs showed a stronger ability to form microspheres and expression of specific stem cell markers was higher in TNBC-derived CSCs than non-TNBC derived CSCs (Fig. 1), which is consistent with previous studies [33].

Emerging evidence showed that microRNAs could regulate key features of BCSCs as oncogenes or tumor suppressor genes. Dysregulated expression levels of microRNAs have been related to poor prognosis and poor therapeutic efficiency in patients with breast cancer [35]. However, there is little information about the TNBC-specific microRNAs in regulating CSC ability. In this study, we detected the TNBC-derived, CSCs-related microRNAs expression panel utilizing Solexa sequencing, and the data showed that 112 microRNAs were upregulated and 81 were downregulated in MDA-MB-468-derived CSCs compared to BT474 CSCs (Fig. 2), including 13 novel microRNAs and 28 microRNAs that have been identified in regulating TNBC malignancies, which might play important roles in the control of CSC hallmark functions, such as self-renewal, tumorsphere formation, and metastasis. We performed bioinformatic analysis for further study and the results of GO and KEGG pathway analysis showed that these microRNAs were mainly involved in pluripotency maintenance of CSCs. Biological process of the microRNA-target genes most contained stem cell development, embryonic morphogenesis, and regulation of stem cell differentiation. The Notch pathway and MAPK signaling pathway have been reported to regulate the self-renewal of stem cells and dysregulation [36]. The results of GO and KEGG pathway analysis indicated that target genes of these differently expressed microRNAs probably were involved in maintenance of stemness and contributed to the differential properties (such as self-renewal, microsphere formation, chemoresistance, and invasion) between TNBC-CSCs and non-TNBC-CSCs (Fig. 4A-4F).

The expression levels of microRNAs (cutoff level of fold-change ≥ 2.0 or ≤ 0.5), were verified by qRT-PCR and 6 of 10 showed stable expression in TNBC CSCs (Fig. 3). MiR-4319 is an unknown miRNA, and showed a stable low expression level in TNBC CSCs, compared to non-TNBC CSCs. It has been reported that miR-4319 was related to acute myeloid leukemia [37], whereas the brief function and mechanism are not clear. In this study, we investigated the effect of miR-4319 in TNBC CSCs as well as the underlying mechanism. Overexpression of miR-4319 could significantly suppress tumorsphere formation and growth in suspension (Fig. 5A, 5C). The specific stem cell markers also were downregulated simultaneously (Fig.

5D). The results showed the reverse in the miR-4319-KD group. Nude mouse transplantation tumor experimentation showed the same results as *in vitro* experiments. Compared to control, overexpression of miR-4319 inhibited the capacity of self-renewal, tumor formation, and extensive metastases of TNBC CSCs whereas miR-4319 knockdown could significantly enhance the tumorigenicity of stem cells and consequently be responsible for extensive metastasis in TNBC (Fig. 6). Together, these findings supported the hypothesis that miR-4319 was involved in regulating biological function of stem cells and inhibited the tumorigenesis, progression, and metastasis of TNBC CSCs.

MicroRNAs participate in a series of cellular processes by binding to 3' UTR of target mRNA, and then inducing targeted messenger RNA (mRNA) slicing by Dicer complex in the cytoplasm [38]. Bioinformatics analysis results (TargetScan) and microarray data indicated that *E2F2* was the potential target gene of miR-4319. Furthermore, there were three miR-4319 binding sites (1446, bp ~1452, bp, 1481, bp ~1488, bp, and 1863, bp ~1870, bp) in 3' UTR of *E2F2* mRNA, and the luciferase assay results showed that miR-4319 could bind to each site to reduce the expression of *E2F2*. Moreover, overexpression of *E2F2* abolished the effect of miR-4319 on the self-renewal and tumorigenicity in TNBC CSCs. *E2F2* is a member of the E2F family of transcription factors. It plays a central role in regulating G1/S transition and progression through S phase, promoting cellular transformation [39]. Previous studies have reported that *E2F2* is a transcription factor with important functions in the control of embryonic development and differentiation [40]. *E2F2* is also essential for self-renewal of stem cells by inducing the transcription of oncogenes typically associated with poor prognosis, such as BMI1 and MELK [41, 42]. Hence, miR-4319 might reduce the stemness of TNBC CSCs mainly through inhibition of *E2F2* expression.

Our data elucidated the differences in miRNA expression patterns between TNBC and non-TNBC CSC subpopulation, and further investigated the effect of miR-4319 on BCSCs as well as the underlying mechanism: we identified miR-4319 as a tumor suppressor gene in the maintenance of CSC stemness and confirmed that miR-4319 could inhibit the tumor initiation and metastasis of CSCs mainly through downregulation of *E2F2*, which afforded the database to help understand the aggressive phenotype of TNBC. However, the retrospective analysis indicated that the stemness of TNBC-CSCs may be regulated by a series of miRNAs, and the correlation between miRNAs network and TNBC-CSCs requires further confirmation. In conclusion, miR-4319 plays an important role in regulating the self-renewal and tumorigenicity of stem cells and might be a remarkable prognostic factor or therapeutic target for patients with TNBC.

Acknowledgements

This study was financially supported by the National Natural Science Foundation of China (81172503, 81302304, 81572603, and 81570804), Key projects of Jiangsu Health Department (RC201153), the Second Level of 333 Project of Jiangsu Province (BRA2017534), the Third Level of 333 Project of Jiangsu Province (BRA2015470), the Project of Jiangsu Provincial Medical Talent (ZDRCA2016023), the Project of Jiangsu Provincial Medical youth Talent (QNRC2016095), General Project of Nanjing Health Bureau (YKK17179), and the Project of Wu Jieping Medical Foundation (320.6750.17006).

The miRNA-seq data in this paper are deposited to GEO (<http://www.ncbi.nlm.nih.gov/geo/>) with accession number GEO: GSE97765.

Disclosure Statement

The authors declare that there is no conflict of interests.

References

- 1 Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 2007;13:4429-4434.
- 2 Venkitaraman R: Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. *Expert Rev Anticancer Ther* 2010;10:199-207.
- 3 Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang W, Yin Y, Guan X: Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. *Cell Physiol Biochem* 2016;38:1003-1014.
- 4 Valsecchi ME, Kimmey G, Bir A, Silbermins D: Role of Carboplatin in the Treatment of Triple Negative Early-Stage Breast Cancer. *Rev Recent Clin Trials* 2015;10:101-110.
- 5 Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. *N Engl J Med* 2010;363:1938-1948.
- 6 Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* 2007;109:1721-1728.
- 7 Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest* 2011;121:2750-2767.
- 8 Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B: Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). *Cancer Lett* 2014;353:153-159.
- 9 Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV: Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. *PLoS One* 2013;8:e78259.
- 10 Rosen JM, Jordan CT: The increasing complexity of the cancer stem cell paradigm. *Science* 2009;324:1670-1673.
- 11 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003;100:3983-3988.
- 12 Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Res* 2009;69:1302-1313.
- 13 Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G: Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. *J Oncol* 2011;2011:620523.
- 14 Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast-cancer cells. *N Engl J Med* 2007;356:217-226.
- 15 Idowu MO, Kmiecik M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH: CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. *Hum Pathol* 2012;43:364-373.
- 16 Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S: Inhibition of microRNA function by anti-miR oligonucleotides. *Silence* 2012;3:1.
- 17 Kasinski AL, Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nat Rev Cancer* 2011;11:849-864.
- 18 Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, Lin WC, Shen CY, Huang CS, Hsieh FJ, Lai LC, Tsai MH, Chang KJ, Chuang EY: Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. *Mol Cancer* 2015;14:36.
- 19 Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J, Ye F, Guo X, Zheng W, Zheng Y, Shu XO: Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. *Breast Cancer Res Treat* 2015;152:183-191.
- 20 Gyparaki MT, Basdra EK, Papavassiliou AG: MicroRNAs as regulatory elements in triple negative breast cancer. *Cancer Lett* 2014;354:1-4.
- 21 Croce CM, Calin GA: miRNAs, cancer, and stem cell division. *Cell* 2005;122:6-7.

- 22 Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* 2007;131:1109-1123.
- 23 Yu F, Deng H, Yao H, Liu Q, Su F, Song E: Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. *Oncogene* 2010;29:4194-4204.
- 24 Xu P, Wang L, Huang L, Li W, Lv S, Lv M, Ma J, Zhou Q, Wu X, Fu Z, Lu C, Yin H: Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology. *Biomed Pharmacother* 2015;75:173-178.
- 25 Mimoto R, Imawari Y, Hirooka S, Takeyama H, Yoshida K: Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer. *Oncogene* 2017;36:1862-1872.
- 26 Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T: Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. *Cancer Lett* 2017;394:52-64.
- 27 Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE: A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. *Cancer Res* 2016;76:480-490.
- 28 Boyle ST, Gieniec KA, Gregor CE, Faulkner JW, McColl SR, Kochetkova M: Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells. *Mol Cancer* 2017;16:19.
- 29 Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, Baev V: Characterization of the uterine leiomyoma microRNAome by deep sequencing. *Genomics* 2012;99:275-281.
- 30 Sdassi N, Silveri L, Laubier J, Tilly G, Costa J, Layani S, Vilotte JL, Le Provost F: Identification and characterization of new miRNAs cloned from normal mouse mammary gland. *BMC Genomics* 2009;10:149.
- 31 Muller L, Muller-Haegeler S, Mitsunashi M, Gooding W, Okada H, Whiteside TL: Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. *Oncoimmunology* 2015;4:e1008347.
- 32 Akrap N, Andersson D, Bom E, Gregersson P, Stahlberg A, Landberg G: Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools. *Stem Cell Reports* 2016;6:121-136.
- 33 Oliveras-Ferreros C, Vazquez-Martin A, Martin-Castillo B, Cufi S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA: Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). *Biochem Biophys Res Commun* 2010;397:27-33.
- 34 Hafner M, Landgraf P, Ludwig J, Rice A, Ojo T, Lin C, Holoch D, Lim C, Tuschl T: Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. *Methods* 2008;44:3-12.
- 35 Bertoli G, Cava C, Castiglioni I: MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. *Theranostics* 2015;5:1122-1143.
- 36 Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61-70.
- 37 Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Minervini A, Specchia G: SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. *J Hematol Oncol* 2012;5:48.
- 38 Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15-20.
- 39 Helin K: Regulation of cell proliferation by the E2F transcription factors. *Curr Opin Genet Dev* 1998;8:28-35.
- 40 Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K: E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. *Genes Dev* 2001;15:267-285.
- 41 Yang N, Zhou TC, Lei XX, Wang C, Yan M, Wang ZF, Liu W, Wang J, Ming KH, Wang BC, Xu BL, Liu Q: Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24- Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer. *Cell Physiol Biochem* 2016;38:1157-1170.
- 42 Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, Nakano I: Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. *Stem Cells* 2013;31:870-881.